J Endod:长期肽类接触对牙本质小管内单一或多种生物膜的影响

2019-10-17 lishiting MedSci原创

这篇研究的目的是为了评估单一使用2%氯己定(CHX)和肽1018及DJK-5或混合使用(peptide and 2% CHX)分别在短期和长期应用时对根管内粪肠球菌和多种属生物膜的影响。

这篇研究的目的是为了评估单一使用2%氯己定(CHX)和肽1018及DJK-5或混合使用(peptide and 2% CHX)分别在短期和长期应用时对根管内粪肠球菌和多种属生物膜的影响。

研究准备了180个牙本质块,并通过离心法充填了粪肠球菌或多菌属细菌。培养3周后,牙本质内的生物膜暴露于2% CHX, DJK-5 (10 μg/mL), 1018 (10 μg/mL), DJK-5 + 2% CHX或1018 + 2% CHX,短期应用时间为1或3分钟, 短期应用24小时后再进行24小时的接触为长期应用。通过活/死细菌的活性染色以及激光共聚焦显微镜检测抗菌效果。

结果显示,肽DJK-5伴随CHX与否是抗所有生物膜的最有效方法(P < .05),能够在1分钟内杀灭77%的菌斑生物膜。DJK-5或DJK-5 + CHX在最初暴露的3分钟内(>81%)和暴露24小时后(83%),对于细菌的杀灭程度之间未见明显差异。 氯己定和肽1018的抗生物膜效果弱于DJK-5,并且它们的效果具有时间依赖性(P < .05),在暴露24小时后最大杀菌率为60%。

结论:单独使用肽DJK-5或联合氯己定对牙本质感染具有快速杀菌效果。CHX 和肽1018在暴露24小时后展现出额外的抗菌作用。

原始出处:

Huang X, Haapasalo M, et al. Effect of Long-term Exposure to Peptides on Mono- and Multispecies Biofilms in Dentinal Tubules. J Endod. 2019 Oct 9. pii: S0099-2399(19)30659-4. doi: 10.1016/j.joen.2019.09.003.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1642320, encodeId=e3a216423208d, content=<a href='/topic/show?id=fc7a6e56449' target=_blank style='color:#2F92EE;'>#牙本质小管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67564, encryptionId=fc7a6e56449, topicName=牙本质小管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22df22898970, createdName=ms1948154235210413, createdTime=Fri Apr 17 01:05:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374110, encodeId=b4cc3e411052, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 19 12:05:37 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441968, encodeId=4c161441968a8, content=<a href='/topic/show?id=67526e55924' target=_blank style='color:#2F92EE;'>#牙本质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67559, encryptionId=67526e55924, topicName=牙本质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37364903098, createdName=ms8538335253054589, createdTime=Sat Oct 19 02:05:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374036, encodeId=67eb3e403666, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Thu Oct 17 11:19:03 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1642320, encodeId=e3a216423208d, content=<a href='/topic/show?id=fc7a6e56449' target=_blank style='color:#2F92EE;'>#牙本质小管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67564, encryptionId=fc7a6e56449, topicName=牙本质小管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22df22898970, createdName=ms1948154235210413, createdTime=Fri Apr 17 01:05:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374110, encodeId=b4cc3e411052, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 19 12:05:37 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441968, encodeId=4c161441968a8, content=<a href='/topic/show?id=67526e55924' target=_blank style='color:#2F92EE;'>#牙本质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67559, encryptionId=67526e55924, topicName=牙本质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37364903098, createdName=ms8538335253054589, createdTime=Sat Oct 19 02:05:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374036, encodeId=67eb3e403666, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Thu Oct 17 11:19:03 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2019-10-19 1ddf0692m34(暂无匿称)

    学习了,谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1642320, encodeId=e3a216423208d, content=<a href='/topic/show?id=fc7a6e56449' target=_blank style='color:#2F92EE;'>#牙本质小管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67564, encryptionId=fc7a6e56449, topicName=牙本质小管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22df22898970, createdName=ms1948154235210413, createdTime=Fri Apr 17 01:05:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374110, encodeId=b4cc3e411052, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 19 12:05:37 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441968, encodeId=4c161441968a8, content=<a href='/topic/show?id=67526e55924' target=_blank style='color:#2F92EE;'>#牙本质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67559, encryptionId=67526e55924, topicName=牙本质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37364903098, createdName=ms8538335253054589, createdTime=Sat Oct 19 02:05:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374036, encodeId=67eb3e403666, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Thu Oct 17 11:19:03 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1642320, encodeId=e3a216423208d, content=<a href='/topic/show?id=fc7a6e56449' target=_blank style='color:#2F92EE;'>#牙本质小管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67564, encryptionId=fc7a6e56449, topicName=牙本质小管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22df22898970, createdName=ms1948154235210413, createdTime=Fri Apr 17 01:05:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374110, encodeId=b4cc3e411052, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Oct 19 12:05:37 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441968, encodeId=4c161441968a8, content=<a href='/topic/show?id=67526e55924' target=_blank style='color:#2F92EE;'>#牙本质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67559, encryptionId=67526e55924, topicName=牙本质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37364903098, createdName=ms8538335253054589, createdTime=Sat Oct 19 02:05:00 CST 2019, time=2019-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374036, encodeId=67eb3e403666, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Thu Oct 17 11:19:03 CST 2019, time=2019-10-17, status=1, ipAttribution=)]
    2019-10-17 一天没事干

    很好的学习机会

    0

相关资讯

Cancer Res:科学家发现肿瘤释放杀手肽,竟能将耐药癌细胞同伙“一网打尽”

在肯塔基大学的一项新研究中,癌症中心研究人员表明,对疗法敏感的癌细胞死亡死亡之后,他们释放一个“杀手级肽”,,可以将抵抗治疗的癌细胞一网打尽。

Nature Medicine:利用一种肽,成功治疗肥胖症患者

“我们还想确定为什么这种肽如此有效,为什么与其它具有相似作用模式的制剂相比,这种肽没有产生任何严重的副作用?”

Cancer Sci:雄激素抵抗性前列腺癌中细胞分裂相关1(CDCA1)肽接种疫苗**阶段临床试验

最近,研究人员筛选了细胞分裂相关1(CDCA1),并且作为致癌基因在几种癌症,包括前列腺癌中超表达。研究人员同样鉴定了一个高度免疫的HLA-A*2402限制性表位多肽,并且与CDCA1蛋白的部分一致。另外,利用CDCA1肽接种疫苗,对患有雄激素抵抗性前列腺癌(CRPC)的病人进行了第一阶段的临床试验。研究包括了多烯紫杉醇化疗失败的具有HLA-A*2402的12名CRPC病人,并让他们接受带有Mon

PNAS:创新突破 滴血验癌

尽管医学发展取得了一些令人惊叹的成果,癌症仍是人类的头号杀手,给我们的医疗系统带来了沉重的负担。在疾病的早期对癌症进行诊断和干预是降低人力和经济损失的关键。   来自亚利桑那州立大学的研究人员开发了一种创新性的疾病检测技术,其可以基于癌症引发的免疫反应对几种常见的癌症进行检测。他们将其命名为免疫标记(immunosignaturing)技术。研究结果发表在7月14日的《美国国家科学院

Aravax基于肽的免疫疗法治疗花生过敏展现出积极有利的1期临床试验结果

Aravax在2019年美国过敏、哮喘和免疫学会(AAAAI)年会上展示了最近完成的PVX108的第1阶段临床试验的阳性数据。数据充分肯定了PVX108的安全性,即使对严重花生过敏的患者也是如此。与花生过敏的其他治疗方法相比,这是一个显着的进步。

J Dent:中国儿童早期龋损发展中唾液蛋白组学概况的纵向调查研究

这篇研究为了调查分析3-4岁儿童早期龋损(ECC)发展过程中唾液内不同的肽表达。